Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHVN Biohaven	$14.20 -1.3%	$14.56	$12.79 ▼ $55.70	$1.50B	0.98	1.68 million shs	1.15 million shs
EWTX Edgewise Therapeutics	$13.93 +1.5%	$13.95	$10.60 ▼ $38.12	$1.47B	0.26	1.24 million shs	386,926 shs
GTHX G1 Therapeutics	$7.15	$7.13	$1.08 ▼ $7.19	$373.81M	1.66	1.70 million shs	N/A
JANX Janux Therapeutics	$24.97 +0.0%	$24.62	$21.97 ▼ $71.71	$1.50B	2.86	946,264 shs	779,858 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHVN Biohaven	+7.06%	-4.47%	+1.61%	-8.86%	-63.34%
EWTX Edgewise Therapeutics	+2.54%	+1.55%	-1.44%	-4.98%	-19.66%
GTHX G1 Therapeutics	0.00%	0.00%	0.00%	0.00%	+0.99%
JANX Janux Therapeutics	+2.84%	+3.23%	-4.66%	+7.26%	-34.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHVN Biohaven	3.1996 of 5 stars	4.5	1.0	0.0	0.0	2.2	2.5	0.6
EWTX Edgewise Therapeutics	1.9511 of 5 stars	3.5	2.0	0.0	0.0	2.3	1.7	0.0
GTHX G1 Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	2.5117 of 5 stars	3.5	2.0	0.0	0.0	2.2	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHVN Biohaven	3.07	Buy	$53.75	278.49% Upside
EWTX Edgewise Therapeutics	2.90	Moderate Buy	$41.60	198.64% Upside
GTHX G1 Therapeutics	0.00	N/A	N/A	N/A
JANX Janux Therapeutics	3.08	Buy	$91.89	268.00% Upside

Current Analyst Ratings Breakdown

Latest GTHX, BHVN, EWTX, and JANX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	BHVN Biohaven	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $30.00
8/12/2025	BHVN Biohaven	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $50.00
8/12/2025	BHVN Biohaven	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$63.00 ➝ $54.00
8/12/2025	BHVN Biohaven	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $52.00
8/12/2025	BHVN Biohaven	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $49.00
8/8/2025	EWTX Edgewise Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$48.00 ➝ $49.00
7/30/2025	EWTX Edgewise Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$46.00
7/11/2025	JANX Janux Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
6/30/2025	EWTX Edgewise Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
6/18/2025	BHVN Biohaven	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$68.00 ➝ $55.00
6/5/2025	EWTX Edgewise Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$48.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHVN Biohaven	N/A	N/A	N/A	N/A	$1.27 per share	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$5.59 per share	N/A
GTHX G1 Therapeutics	$58.20M	6.42	N/A	N/A	$0.68 per share	10.51
JANX Janux Therapeutics	$439K	3,418.10	N/A	N/A	$16.48 per share	1.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHVN Biohaven	-$846.42M	-$7.66	N/A	N/A	N/A	N/A	-270.65%	-143.70%	8/14/2025 (Estimated)
EWTX Edgewise Therapeutics	-$133.81M	-$1.55	N/A	N/A	N/A	N/A	-30.65%	-29.18%	8/14/2025 (Estimated)
GTHX G1 Therapeutics	-$47.97M	-$0.62	N/A	N/A	N/A	-76.93%	-136.98%	-39.33%	N/A
JANX Janux Therapeutics	-$68.99M	-$1.80	N/A	N/A	N/A	N/A	-11.48%	-11.01%	N/A

Latest GTHX, BHVN, EWTX, and JANX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q1 2025	BHVN Biohaven	-$1.94	-$1.94	N/A	-$1.94	$0.41 million	N/A
8/7/2025	Q2 2025	EWTX Edgewise Therapeutics	-$0.42	-$0.34	+$0.08	-$0.34	N/A	N/A
8/7/2025	Q2 2025	JANX Janux Therapeutics	-$0.48	-$0.55	-$0.07	-$0.55	$0.30 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
GTHX G1 Therapeutics	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHVN Biohaven	1.91	3.82	2.33
EWTX Edgewise Therapeutics	N/A	28.87	20.99
GTHX G1 Therapeutics	1.34	2.48	2.12
JANX Janux Therapeutics	N/A	47.03	47.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHVN Biohaven	88.78%
EWTX Edgewise Therapeutics	N/A
GTHX G1 Therapeutics	24.21%
JANX Janux Therapeutics	75.39%

Insider Ownership

Company	Insider Ownership
BHVN Biohaven	16.00%
EWTX Edgewise Therapeutics	23.20%
GTHX G1 Therapeutics	6.11%
JANX Janux Therapeutics	8.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHVN Biohaven	239	105.79 million	85.78 million	Optionable
EWTX Edgewise Therapeutics	60	105.35 million	80.91 million	Optionable
GTHX G1 Therapeutics	170	52.28 million	49.09 million	Optionable
JANX Janux Therapeutics	30	60.09 million	55.23 million	Optionable

GTHX, BHVN, EWTX, and JANX Headlines

Recent News About These Companies

HC Wainwright Expects Higher Earnings for Janux Therapeutics

August 14 at 8:22 AM | marketbeat.com

HC Wainwright Analysts Boost Earnings Estimates for JANX

August 14 at 2:25 AM | americanbankingnews.com

HC Wainwright Has Bearish Estimate for JANX FY2029 Earnings

August 13 at 8:55 AM | marketbeat.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Recommendation of "Buy" by Brokerages

August 11 at 3:22 AM | marketbeat.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Recommendation of "Buy" by Analysts

August 10, 2025 | americanbankingnews.com

Janux Therapeutics (NASDAQ:JANX) Reaches New 52-Week Low After Earnings Miss

August 10, 2025 | americanbankingnews.com

Janux Therapeutics (NASDAQ:JANX) Reaches New 12-Month Low After Earnings Miss

August 9, 2025 | marketbeat.com

Janux Therapeutics (NASDAQ:JANX) Trading 8.6% Higher - Here's What Happened

August 6, 2025 | marketbeat.com

Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck

August 5, 2025 | businesswire.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Stock Position Decreased by TD Asset Management Inc

August 5, 2025 | marketbeat.com

Janux Therapeutics (JANX) Expected to Announce Quarterly Earnings on Wednesday

July 31, 2025 | marketbeat.com

Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash

July 31, 2025 | seekingalpha.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Bank of New York Mellon Corp

July 29, 2025 | marketbeat.com

Skandinaviska Enskilda Banken AB publ Sells 27,347 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

July 28, 2025 | marketbeat.com

Y Intercept Hong Kong Ltd Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

July 28, 2025 | marketbeat.com

Victory Capital Management Inc. Purchases 23,242 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

July 26, 2025 | marketbeat.com

Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

July 24, 2025 | businesswire.com

Readystate Asset Management LP Cuts Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

July 22, 2025 | marketbeat.com

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Sells 52,896 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

July 22, 2025 | marketbeat.com

Janux Therapeutics (NASDAQ:JANX) Stock Price Down 3.8% - Here's What Happened

July 19, 2025 | marketbeat.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by Nisa Investment Advisors LLC

July 19, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTHX, BHVN, EWTX, and JANX Company Descriptions

Biohaven NYSE:BHVN

$14.20 -0.19 (-1.31%)

Closing price 03:59 PM Eastern

Extended Trading

$14.23 +0.03 (+0.20%)

As of 04:20 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Edgewise Therapeutics NASDAQ:EWTX

$13.93 +0.20 (+1.46%)

Closing price 04:00 PM Eastern

Extended Trading

$13.92 -0.01 (-0.07%)

As of 04:20 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

G1 Therapeutics NASDAQ:GTHX

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Janux Therapeutics NASDAQ:JANX

$24.97 +0.01 (+0.04%)

Closing price 04:00 PM Eastern

Extended Trading

$25.20 +0.23 (+0.90%)

As of 04:20 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time